CHOP Plus Mosunetuzumab as First Line in Patients With Richter´s Syndrome: a Phase II Study of the Spanish Group of CLL

NCT06926205 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Richter Syndrome

Interventions

DRUG: Mosunetuzumab (IV)

Sponsor

GELLC (Grupo Español de Leucemia Linfocítica Crónica)

Collaborators

[object Object]